The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.
News & Analysis: Roche Holding Ltd. (ADR)
Regeneron's REGN-COV2 is a leading candidate to treat the illness.
Roche and PTC Therapeutics will challenge Novartis and Biogen with competitive pricing for Evrysdi.
Actemra fails another clinical trial, but there are still two ongoing late-stage studies.
The performance of the very timely product category cushioned declines in the company's other businesses.
Large drugmakers are hoping to stop a looming global crisis that could be much worse than COVID-19.
There are still two ongoing studies of the drug in patients infected with the novel coronavirus.
Both companies have moved aggressively to produce diagnostic tests for COVID-19, and both are positioned for growth.
They're both leaders in COVID-19 diagnostics testing and a whole lot more. But one stock appears to be the better pick right now.
The new diagnostic tool measures whether a person has developed antibodies for SARS-CoV-2.